Reinhardt Anita, Köhler Thilo, Wood Paul, Rohner Peter, Dumas Jean-Luc, Ricou Bara, van Delden Christian
Département de Microbiologie et de Médecine Moléculaire, Centre Médical Universitaire de Genève, and Laboratoire Central de Bactériologie, Service des Soins Intensifs, Hôpital Universitaire de Genève, Geneva, Switzerland.
Antimicrob Agents Chemother. 2007 Apr;51(4):1341-50. doi: 10.1128/AAC.01278-06. Epub 2007 Jan 29.
Intubated patients frequently become colonized by Pseudomonas aeruginosa, which is subsequently responsible for ventilator-associated pneumonia. This pathogen readily acquires resistance against available antimicrobials. Depending on the resistance mechanism selected for, resistance might either be lost or persist after removal of the selective pressure. We investigated the rapidity of selection, as well as the persistence, of antimicrobial resistance and determined the underlying mechanisms. We selected 109 prospectively collected P. aeruginosa tracheal isolates from two patients based on their prolonged intubation and colonization periods, during which they had received carbapenem, fluoroquinolone (FQ), or combined beta-lactam-aminoglycoside therapies. We determined antimicrobial resistance phenotypes by susceptibility testing and used quantitative real-time PCR to measure the expression of resistance determinants. Within 10 days after the initiation of therapy, all treatment regimens selected resistant isolates. Resistance to beta-lactam and FQ was correlated with ampC and mexC gene expression levels, respectively, whereas imipenem resistance was attributable to decreased oprD expression. Combined beta-lactam-aminoglycoside resistance was associated with the appearance of small-colony variants. Imipenem and FQ resistance persisted for prolonged times once the selecting antimicrobial treatment had been discontinued. In contrast, resistance to beta-lactams disappeared rapidly after removal of the selective pressure, to reappear promptly upon renewed exposure. Our results suggest that resistant P. aeruginosa is selected in less than 10 days independently of the antimicrobial class. Different resistance mechanisms lead to the loss or persistence of resistance after the removal of the selecting agent. Even if resistant isolates are not evident upon culture, they may persist in the lung and can be rapidly reselected.
气管插管患者常被铜绿假单胞菌定植,随后该菌会引发呼吸机相关性肺炎。这种病原体很容易获得对现有抗菌药物的耐药性。根据所选择的耐药机制,在去除选择压力后,耐药性可能会消失或持续存在。我们研究了抗菌药物耐药性的选择速度以及持续性,并确定了其潜在机制。我们基于两名患者较长的插管和定植期,前瞻性收集了109株铜绿假单胞菌气管分离株,在此期间他们接受了碳青霉烯类、氟喹诺酮(FQ)或β-内酰胺类-氨基糖苷类联合治疗。我们通过药敏试验确定抗菌药物耐药表型,并使用定量实时PCR测量耐药决定子的表达。在治疗开始后的10天内,所有治疗方案都选择出了耐药菌株。对β-内酰胺类和FQ的耐药性分别与ampC和mexC基因表达水平相关,而亚胺培南耐药性归因于oprD表达降低。β-内酰胺类-氨基糖苷类联合耐药性与小菌落变体的出现有关。一旦停止选择抗菌治疗,亚胺培南和FQ耐药性会持续较长时间。相比之下,去除选择压力后,对β-内酰胺类的耐药性迅速消失,再次接触后又会迅速重新出现。我们的结果表明,无论抗菌药物类别如何,耐药铜绿假单胞菌在不到10天内即可被选择出来。不同的耐药机制导致在去除选择剂后耐药性的丧失或持续存在。即使培养时未发现耐药菌株,它们也可能在肺部持续存在并可迅速重新被选择出来。